ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Chinese biopharma Taibang raises $300m, stirs relisting murmurs

Investment in former China Biologic led by Singapore, Abu Dhabi funds

Singaporean sovereign wealth fund GIC co-led the $300 million fundraising round for Taibang Biologic.   © Reuters

SHANGHAI -- Taibang Biologic Group has raised $300 million from investors including the Abu Dhabi Investment Authority and Singaporean sovereign wealth fund GIC, the Chinese company said Tuesday.

The biopharmaceutical company, formerly known as China Biologic Products, was previously listed on Nasdaq. It was taken private in April 2021 by a consortium led by Beijing-based Centurium Capital to focus its resources on the Chinese market.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more